Join
Live feed
·
NEWSReleasevia Quantisnow
MIRA Pharmaceuticals Inc. logo

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

ByQuantisnow·Wall Street's wire, on your screen.
MIRA· MIRA Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MIRA (MIRA Pharmaceuticals Inc.) and more on Quantisnow.